Focused On-demand Library for Transcription regulator protein BACH2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9BYV9

UPID:

BACH2_HUMAN

Alternative names:

BTB and CNC homolog 2

Alternative UPACC:

Q9BYV9; E1P518; Q59H70; Q5T793; Q9NTS5

Background:

Transcription regulator protein BACH2, also known as BTB and CNC homolog 2, plays a pivotal role in cellular processes, including transcription regulation, apoptosis in response to oxidative stress, and nuclear import of actin. It binds to Maf recognition elements, coordinating transcription activation and repression by MAFK, and is crucial for adaptive immunity, regulatory T-cell function, and B-cell maturation.

Therapeutic significance:

BACH2's involvement in Immunodeficiency 60 and autoimmunity, a disorder characterized by intestinal inflammation, recurrent infections, and impaired lymphocyte maturation, highlights its potential as a target for therapeutic intervention. Understanding the role of BACH2 could open doors to potential therapeutic strategies.